Literature DB >> 34734308

Immunosuppression in Rheumatologic and Auto-immune Disease.

Arundathi Jayatilleke1.   

Abstract

Many rheumatologic diseases are thought to originate in dysregulation of the immune system; lupus nephritis, for example, involves humoral immunity, while autoinflammatory diseases such as familial Mediterranean fever are caused by defects in innate immunity. Of note, this dysregulation may involve both upregulation of immune system components and aspects of immunodeficiency. Treatment of rheumatologic diseases thus requires a familiarity with a variety of immunosuppressive medications and their effects on immune system function.In many rheumatologic conditions, due to an incompletely elucidated mechanism of disease, immunosuppression is relatively broad in contrast to agents used, for example, in treatment of transplant rejection. Multiple immunosuppressive drugs may also be used in succession or in combination. As such, an understanding of the mechanisms and targets of immunosuppressive drugs is essential to appreciating their utility and potential adverse effects. Because of the overlap between therapies used in rheumatologic as well as other inflammatory disorders, some of these medications are discussed in other disease processes (e.g., Immunosuppression for inflammatory bowel disease) or in greater detail in other chapters of this textbook (corticosteroids, mTOR inhibitors, antiproliferative agents).
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Autoimmune; Autoinflammatory; Biologics; DMARDs; Immunosuppressants; Lupus; Rheumatoid arthritis; Rheumatology; Vasculitis

Mesh:

Substances:

Year:  2022        PMID: 34734308     DOI: 10.1007/164_2021_551

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  132 in total

1.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Authors:  Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

2.  An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.

Authors:  Ivona Aksentijevich; Seth L Masters; Polly J Ferguson; Paul Dancey; Joost Frenkel; Annet van Royen-Kerkhoff; Ron Laxer; Ulf Tedgård; Edward W Cowen; Tuyet-Hang Pham; Matthew Booty; Jacob D Estes; Netanya G Sandler; Nicole Plass; Deborah L Stone; Maria L Turner; Suvimol Hill; John A Butman; Rayfel Schneider; Paul Babyn; Hatem I El-Shanti; Elena Pope; Karyl Barron; Xinyu Bing; Arian Laurence; Chyi-Chia R Lee; Dawn Chapelle; Gillian I Clarke; Kamal Ohson; Marc Nicholson; Massimo Gadina; Barbara Yang; Benjamin D Korman; Peter K Gregersen; P Martin van Hagen; A Elisabeth Hak; Marjan Huizing; Proton Rahman; Daniel C Douek; Elaine F Remmers; Daniel L Kastner; Raphaela Goldbach-Mansky
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

Review 3.  Mycophenolate mofetil and its mechanisms of action.

Authors:  A C Allison; E M Eugui
Journal:  Immunopharmacology       Date:  2000-05

Review 4.  Mechanisms of action of mycophenolate mofetil.

Authors:  A C Allison
Journal:  Lupus       Date:  2005       Impact factor: 2.911

Review 5.  T-cell regulation by CD28 and CTLA-4.

Authors:  M L Alegre; K A Frauwirth; C B Thompson
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

Review 6.  Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.

Authors:  Beatrix Bartok; Gary S Firestein
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

7.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.

Authors:  H A Austin; J H Klippel; J E Balow; N G le Riche; A D Steinberg; P H Plotz; J L Decker
Journal:  N Engl J Med       Date:  1986-03-06       Impact factor: 91.245

8.  Successful treatment of class V+IV lupus nephritis with multitarget therapy.

Authors:  Hao Bao; Zhi-Hong Liu; Hong-Lang Xie; Wei-Xin Hu; Hai-Tao Zhang; Lei-Shi Li
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

9.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Authors:  Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Isenberg; David Jayne; Lei-Shi Li; Eduardo Mysler; Jorge Sánchez-Guerrero; Neil Solomons; David Wofsy
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121

10.  Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Fan Bai; Gang Gang Li; Qingmin Liu; Xinwu Niu; Ruilian Li; Huiqun Ma
Journal:  J Immunol Res       Date:  2019-09-10       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.